CoChat

Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this newly discovered class of gene expression repressors may be viable therapeutic targets. A microarray of miRNA changes in ALS-model superoxide dismutase 1 (SOD1)(G93A) rodents identified 12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. To test miRNA inhibition in the central nervous system (CNS) as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs throughout the CNS and in the periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, following intraventricular delivery, demonstrated widespread functional distribution in the brain and spinal cord. After treating SOD1(G93A) mice with anti-miR-155, we significantly extended survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 is a promising new therapeutic target for human ALS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/hmg/ddt261

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Esau, C. (2010) In: Keystone Symposia: Diabetes (Z6). Whistler: British Columbia Canada.
  2. D'Urso, P.I., D'Urso, O.F., Storelli, C., Mallardo, M., Gianfreda, C.D., Montinaro, A., Cimmino, A., Pietro, C. and Marsigliante, S. (2012) miR-155 4134 Human Molecular Genetics, 2013, Vol. 22, No. 20

Cited by

See all 243

Metadata

Authors
Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M.
Affiliations
  • Washington University in St. Louis (US)
  • Regulus Therapeutics (United States) (US)
Corresponding author
Miller, Timothy M.
Venue
Human Molecular Genetics
Published
2013-06-04
Volume
22
Issue
20
Pages
4127-4135
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W2106430667
Cited by
236
References
27
Citations by year
2026: 9 · 2025: 16 · 2024: 11 · 2023: 15 · 2022: 11 · 2021: 15 · 2020: 29 · 2019: 13 · 2018: 30 · 2017: 22 · 2016: 17 · 2015: 27 · 2014: 19 · 2013: 2
FWCI
13.75
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Dana Foundation
  • Massachusetts General Hospital
  • Edward Mallinckrodt, Jr. Foundation
  • National Institutes of Health
  • School of Medicine, Stanford University
  • National Institute of Neurological Disorders and Stroke (F31NS077781, K08NS062138, K08NS074194, R01NS078398)
  • Robert Packard Center for ALS Research, Johns Hopkins University
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
miR-155, amyotrophic lateral sclerosis, anti-miR oligonucleotides, microRNA inhibition, SOD1 G93A mice, survival extension, peritoneal macrophages, spinal cord, therapeutic target, antisense oligonucleotides
MeSH terms
Adult, Aged, Amyotrophic Lateral Sclerosis, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Spinal Cord, Superoxide Dismutase, Case-Control Studies, Oligonucleotides, Antisense, MicroRNAs, Mice, Rats, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.